Search research articles
Contact Us
Filters
Showing results (341-350 of 363) with videos related to
Page
of 37
Sort By:
HIV Medicine
|
September 4, 2010
Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT)
S L Pett, C Carey, E Lin, et al.
AIDS Research and Human Retroviruses
|
December 2, 1999
Effect of long-term infection with nef-defective attenuated HIV type 1 on CD4+ and CD8+ T lymphocytes: increased CD45RO+CD4+ T lymphocytes and limited activation of CD8+ T lymphocytes
J J Zaunders, A F Geczy, W B Dyer, et al.
The Journal of Infectious Diseases
|
July 29, 2000
Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease
S Emery, W B Capra, D A Cooper, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 19, 2001
A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients
C Ungsedhapand, E D Kroon, S Suwanagool, et al.
Human Vaccines
|
March 15, 2008
Influence of IFNgamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy
S Emery, A D Kelleher, C Workman, et al.
Antimicrobial Agents and Chemotherapy
|
November 16, 2001
Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates
C Rongkavilit, P Thaithumyanon, T Chuenyam, et al.
AIDS (London, England)
|
August 10, 2000
A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration
E D Kroon, C Ungsedhapand, K Ruxrungtham, et al.
Clinical Pharmacology and Therapeutics
|
June 6, 2015
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study
L Dickinson, J Amin, L Else, et al.
Lancet (London, England)
|
July 25, 2006
Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial
, P Yeni, D A Cooper, et al.
Lancet (London, England)
|
June 18, 2013
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study
, M A Boyd, N Kumarasamy, et al.
Page
of 37
Search research articles
Search
Showing results (341-350 of 363) with videos related to
Sort By:
Page
of 37
HIV Medicine
|
September 4, 2010
Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT)
S L Pett, C Carey, E Lin, et al.
AIDS Research and Human Retroviruses
|
December 2, 1999
Effect of long-term infection with nef-defective attenuated HIV type 1 on CD4+ and CD8+ T lymphocytes: increased CD45RO+CD4+ T lymphocytes and limited activation of CD8+ T lymphocytes
J J Zaunders, A F Geczy, W B Dyer, et al.
The Journal of Infectious Diseases
|
July 29, 2000
Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease
S Emery, W B Capra, D A Cooper, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 19, 2001
A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients
C Ungsedhapand, E D Kroon, S Suwanagool, et al.
Human Vaccines
|
March 15, 2008
Influence of IFNgamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy
S Emery, A D Kelleher, C Workman, et al.
Antimicrobial Agents and Chemotherapy
|
November 16, 2001
Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates
C Rongkavilit, P Thaithumyanon, T Chuenyam, et al.
AIDS (London, England)
|
August 10, 2000
A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration
E D Kroon, C Ungsedhapand, K Ruxrungtham, et al.
Clinical Pharmacology and Therapeutics
|
June 6, 2015
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study
L Dickinson, J Amin, L Else, et al.
Lancet (London, England)
|
July 25, 2006
Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial
, P Yeni, D A Cooper, et al.
Lancet (London, England)
|
June 18, 2013
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study
, M A Boyd, N Kumarasamy, et al.
Page
of 37